UroToday2d
ASCO GU 2025: Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) in the US Community Setting.
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...
UroToday3d
EAU 2020: More Porn, Worse Erectile Function
San Francisco, California (UroToday.com) – A study has shown that the amount of porn a man watches is linked to worse erectile function. Watching porn is also associated with greater dissatisfaction ...
UroToday3d
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.
Sarcomatoid urothelial carcinoma (SUC) is a rare histologic subtype with poor prognosis. While there is known intra-tumoral heterogeneity between individual SUC tumors, the relationship between ...
UroToday3d
Comparative analysis of trifecta and pentafecta outcomes in T1a and T1b renal tumors following robotic partial nephrectomy: a retrospective study.
This study aims to conduct a comparative analysis of Trifecta and Pentafecta outcomes between T1a and T1b renal tumors in patients undergoing robotic partial nephrectomy (RAPN). We explore the ...
UroToday3d
Risk of invasive penile cancer after treatment of penile intraepithelial neoplasia.
To examine the risk of progression and time to progression from penile intraepithelial neoplasia (PeIN) to invasive penile cancer in patients treated for PeIN with either surgery, laser ablation or ...
UroToday3d
ASCO GU 2025: Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to the prostate cancer poster session. Dr. Andrei Gafita ...
UroToday3d
ASCO GU 2025: Recurrence after Radiation Therapy: Evaluation, Management, and Outcomes
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Management of Biochemical ...
UroToday3d
ASCO GU 2025: Outcomes for 177Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with mCRPC
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of ...
UroToday3d
Complications - Indwelling Catheters
Catheter related problems due to an indwelling urinary catheter (IUC) have existed as long as urinary catheters have been utilized. This section will review IUC complications: infectious complications ...
UroToday4d
A brief history of urinary catheters
The word “catheter” comes from Greek, meaning “to let or send down.” Catheters were used as early as 3,000 B.C. to relieve painful urinary retention. In those times, many materials were used to form a ...
UroToday4d
Is There a Minimum Percentage of Sarcomatoid Component Required to Affect Outcomes of Localised Renal Cell Carcinoma? - Beyond the Abstract
Sarcomatoid differentiation is an example of epithelial-mesenchymal transition and is present in 5% of localized and 20% of metastatic RCC. Although the impacts of pathological characteristics and the ...
UroToday4d
On-treatment PSA kinetics as a potential biomarker: Guiding personalized treatment in metastatic hormone-sensitive prostate cancer.
In this issue of Med, Bian et al. present a post-hoc analysis of the phase 3 CHART trial investigating rezvilutamide in the metastatic hormone-sensitive prostate cancer setting.1 They show that ...